About Us
Who We Are
How It Started
In 2021, a group of tech visionaries with diverse backgrounds in biopharma and software founded MedaSystems in Silicon Valley. Several of our founders have extensive experience in developing innovative solid tumor cancer therapies, including treatments for aggressive brain cancers like glioblastoma.
During a phase 2 clinical trial for one such therapy, the promising results led physicians to request its availability under FDA-expanded access for patients ineligible for the trial. This revealed a major obstacle, as using spreadsheets and manual methods to track patient information proved inefficient and limited. Our team quickly realized that this issue was widespread, affecting not only biotech startups but also the largest pharmaceutical companies, which process thousands of such requests annually.
Determined to Find a Better Solution
We developed a cutting-edge software platform to automate workflows, collect real-world data, and facilitate seamless interactions between physicians and pharmaceutical manufacturers.
Today, MedaSystems' software is trusted by pharmaceutical companies across the United States and Europe to enhance patient outcomes and streamline the management of drugs under various pre-approval access pathways. Numerous major academic institutions actively use it, and our research and development efforts are grounded in thousands of hours spent collaborating with experts in global pre-approval access.
Our Vision
Our vision has garnered support from experienced healthcare investors, including Young Sohn, a founder of Veeva Systems; Nina Capital, a health-tech venture capital fund; Debiopharm Innovation Fund, the strategic investment arm of Debiopharm; and dedicated members of our management team.